Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.

Lee SJ, Ter Kuile FO, Price RN, Luxemburger C, Nosten F.

PLoS One. 2017 Feb 13;12(2):e0168780. doi: 10.1371/journal.pone.0168780. eCollection 2017.

2.

Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors.

Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C, Proux S, Konghahong K, Jeeyapant A, Woodrow CJ, Imwong M, McGready R, Lwin KM, Day NPJ, White NJ, Nosten F.

Clin Infect Dis. 2016 Sep 15;63(6):784-791. doi: 10.1093/cid/ciw388. Epub 2016 Jun 16.

3.

The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies.

Boni MF, White NJ, Baird JK.

PLoS Med. 2016 Mar 29;13(3):e1001984. doi: 10.1371/journal.pmed.1001984. eCollection 2016 Mar.

4.

Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.

McCarthy S.

J Parasitol Res. 2015;2015:287651. doi: 10.1155/2015/287651. Epub 2015 Dec 17. Review.

5.

Mefloquine inhibits chondrocytic proliferation by arresting cell cycle in G2/M phase.

Li Q, Chen ZG, Xia Q, Lin JP, Yan ZQ, Yao ZJ, Dong J.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12583-8. eCollection 2015.

7.

Mefloquine safety and tolerability in pregnancy: a systematic literature review.

González R, Hellgren U, Greenwood B, Menéndez C.

Malar J. 2014 Feb 28;13:75. doi: 10.1186/1475-2875-13-75. Review.

8.

Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Sibley CH, Price RN.

Int J Parasitol Drugs Drug Resist. 2012 Apr 20;2:126-33. doi: 10.1016/j.ijpddr.2012.03.004. eCollection 2012 Dec. Review.

9.

Modeling within-host effects of drugs on Plasmodium falciparum transmission and prospects for malaria elimination.

Johnston GL, Gething PW, Hay SI, Smith DL, Fidock DA.

PLoS Comput Biol. 2014 Jan;10(1):e1003434. doi: 10.1371/journal.pcbi.1003434. Epub 2014 Jan 23.

10.

Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling.

Yan KH, Yao CJ, Hsiao CH, Lin KH, Lin YW, Wen YC, Liu CC, Yan MD, Chuang SE, Lai GM, Lee LM.

Oncol Lett. 2013 May;5(5):1541-1545. Epub 2013 Feb 22.

11.

Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo.

Yan KH, Lin YW, Hsiao CH, Wen YC, Lin KH, Liu CC, Hsieh MC, Yao CJ, Yan MD, Lai GM, Chuang SE, Lee LM.

Oncol Lett. 2013 May;5(5):1567-1571. Epub 2013 Mar 15.

12.

The anti-malarial drug Mefloquine disrupts central autonomic and respiratory control in the working heart brainstem preparation of the rat.

Lall VK, Dutschmann M, Deuchars J, Deuchars SA.

J Biomed Sci. 2012 Dec 15;19:103. doi: 10.1186/1423-0127-19-103.

13.

Irrational use of antimalarial drugs in rural areas of eastern Pakistan: a random field study.

Khan SY, Khan A, Arshad M, Tahir HM, Mukhtar MK, Ahmad KR, Arshad N.

BMC Public Health. 2012 Nov 1;12:941. doi: 10.1186/1471-2458-12-941.

14.

Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.

Zaloumis S, Humberstone A, Charman SA, Price RN, Moehrle J, Gamo-Benito J, McCaw J, Jamsen KM, Smith K, Simpson JA.

Malar J. 2012 Aug 30;11:303. doi: 10.1186/1475-2875-11-303.

15.

Chemotherapy of drug-resistant malaria.

Kain KC.

Can J Infect Dis. 1996 Jan;7(1):25-33.

16.

Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data.

Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG.

Malar J. 2011 Oct 7;10:292. doi: 10.1186/1475-2875-10-292. Review.

17.

Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area.

Song J, Socheat D, Tan B, Seila S, Xu Y, Ou F, Sokunthea S, Sophorn L, Zhou C, Deng C, Wang Q, Li G.

Malar J. 2011 Aug 10;10:231. doi: 10.1186/1475-2875-10-231.

18.

In vivo parasitological measures of artemisinin susceptibility.

Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U, Day NP, de Vries PJ, Dorsey G, Guthmann JP, Mayxay M, Newton PN, Olliaro P, Osorio L, Price RN, Rowland M, Smithuis F, Taylor WR, Nosten F, White NJ.

J Infect Dis. 2010 Feb 15;201(4):570-9. doi: 10.1086/650301.

19.

Mefloquine pharmacokinetics and mefloquine-artesunate effectiveness in Peruvian patients with uncomplicated Plasmodium falciparum malaria.

Gutman J, Green M, Durand S, Rojas OV, Ganguly B, Quezada WM, Utz GC, Slutsker L, Ruebush TK 2nd, Bacon DJ.

Malar J. 2009 Apr 9;8:58. doi: 10.1186/1475-2875-8-58.

20.

Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.

Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.

Malar J. 2008 Nov 2;7:229. doi: 10.1186/1475-2875-7-229.

Supplemental Content

Support Center